SPY343.38+1.37 0.40%
DIA282.95+0.92 0.33%
IXIC11,516.49+37.51 0.33%

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron aims to create new paradigm of proactive prevention of chemotherapy-induced side effects to address significant unmet need among cancer patients ALRN-6924 is first and only chemoprotective therapy in

· 10/12/2020 07:05
  • Aileron aims to create new paradigm of proactive prevention of chemotherapy-induced side effects to address significant unmet need among cancer patients

  • ALRN-6924 is first and only chemoprotective therapy in clinical development to utilize a biomarker strategy by treating patients with p53-mutated cancers
  • Novel mechanism of action activates wild-type p53 to selectively shield healthy cells from chemotherapy without interrupting chemotherapy’s targeting of cancer cells
  • Company to hold investor call on Monday, October 26, 2020 to discuss the new data and outline strategy to advance chemoprotection across multiple cancers and chemotherapies